UCA1 and lung carcinoma: In addition to the above-described mechanisms, Cheng and colleagues on 2015 reported UCA1 (Urothelial Carcinoma Associated 1) overexpression in lung cancer cells with acquired resistance to gefitinib (PC9/R and H1975), as well as in 37 lung cancer patients with acquired resistance to EGFR-TKIs therapy with exon 19 deletion and/or genetic mutation in exon 21 (L858R) status.